Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
Experimental pancreatic cancer drug offers new hope in major trial
Structured plan for Experimental pancreatic cancer drug offers new hope in major trial
This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test
Structured plan for This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test
Vyome Holdings Q1 2026: FDA Filings and Financial Strength Signal Strategic Momentum
Vyome Holdings announced its first quarter 2026 financial results, underscoring significant progress with key FDA filings and a strengthened balance sheet. The company's performance indicates a strategic focus on regulatory advancement and financial stability.
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing
Structured plan for Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing
Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share
Structured plan for Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share
Top 10 U.S. Biopharma Clusters 2026
Structured plan for Top 10 U.S. Biopharma Clusters 2026
Duchesnay Pharmaceutical Group's Growth Trajectory Five Years Post-Acquisition
Five years after its acquisition by senior management in 2021, Duchesnay Pharmaceutical Group (DPG) has achieved significant and sustained growth across sales, exports, and employment. This expansion solidifies DPG's standing as one of Canada's few comprehensive pharmaceutical businesses.
Inventiva's Strategic Capital Structure: A Deep Dive for Investors and Analysts
Inventiva has announced a significant optimization of its capital structure, incorporating both debt and equity financing. This strategic move is designed to bolster the company's financial position ahead of anticipated Phase 3 clinical trial readouts.
FDA Clears Iovance IL-12 TIL Trial, Signaling New Frontier in Solid Tumor Therapy
The FDA has cleared Iovance Biotherapeutics' Investigational New Drug application for IOV-5001, a novel IL-12 tethered TIL therapy designed for advanced solid tumors. This clearance allows for the initiation of a Phase 1/2 clinical trial, potentially expanding treatment options for patients with difficult-to-treat indications.
Abivax Stock Plummets Amid Safety Concerns in Ulcerative Colitis Trial
Abivax's stock experienced a significant decline of over 37% after releasing new trial data for its ulcerative colitis drug, obefazimod. While the drug demonstrated strong efficacy, the emergence of cancer cases in trial participants has cast a shadow over its prospects.
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
Structured plan for AbiVax falls as safety worries cloud ‘landmark’ immune drug results
FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Structured plan for FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Personalized mRNA cancer vaccines are emerging as a powerful new weapon against melanoma, leveraging individual patient tumor data to create tailored treatments. This innovative approach, building on the success of mRNA technology, shows significant promise in preventing cancer recurrence and offers new hope for patients.
Healthcare AI Market Concentration: Lifecycle Regulation as an Entry Barrier
Lifecycle regulation for AI in healthcare is evolving beyond initial algorithm approval, creating significant entry barriers and leading to market concentration. This shift impacts how new AI solutions are developed, validated, and commercialized.
FDA Overhauls Human Factors Guidance: New Submission Category Introduced
The FDA has updated its human factors guidance, introducing new risk-based submission categories and expanding examples for modified devices. This revision aims to provide clearer frameworks for manufacturers regarding the human factors information required in premarket submissions.
Understanding Computer Software Assurance (CSA) and Its Benefits for Pharma
Computer Software Assurance (CSA) is the FDA's updated, risk-based approach to validating software used in production and quality systems, shifting from traditional, documentation-heavy methods. This new framework emphasizes critical thinking and focuses on patient safety and product quality, offering significant benefits to pharmaceutical companies.
FDA Oncology Draft Guidance: Reducing Animal Testing for Cancer Drugs
The FDA has issued draft guidance aimed at reducing unnecessary animal testing in oncology drug development. This initiative supports expedited pathways for novel treatments while aligning with the agency's commitment to animal welfare.
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Structured plan for Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Navigating the Regulatory Landscape: A Strategic Policy Agenda for Private Equity in Healthcare
Private equity's rapid expansion in the healthcare sector has outpaced current regulatory frameworks. This article outlines a strategic policy agenda necessary to safeguard patients, providers, and the integrity of care delivery.